by Denkstrom
All storiesAfter stem cell therapy: 10 of 12 without insulin

After stem cell therapy: 10 of 12 without insulin

After an infusion of the stem cell therapy Zimislecel, 10 of 12 people with type 1 diabetes who had received a full dose were able to go without external insulin on day 365 of a study. The treatment requires immunosuppression and has so far been developed only for blood groups A and A/B.

The phase 1-2 study of the stem cell therapy Zimislecel was presented on June 20, 2025, at the American Diabetes Association's scientific meeting and published in the New England Journal of Medicine. All 12 participants were free of severe hypoglycemic episodes and spent more than 70% of the time in the target blood glucose range.

How the cells work in the body

Zimislecel, formerly called VX-880, is intended to give people with type 1 diabetes new insulin-producing cells because their own islet cells are impaired by the disease, as the news platform STAT reported. The cells are delivered by infusion into the liver's portal vein, according to the ClinicalTrials.gov study registry. There, they can detect glucose in the blood and produce insulin, according to the diabetes portal diaTribe. To protect the cells from rejection or immune attack, those treated need ongoing immunosuppressive therapy, as the patient organization Breakthrough T1D explained. The organization also reported that the JDRF T1D Fund invested in the company Semma Therapeutics in 2017, which Vertex acquired in 2019 for nearly $1 billion. The clinical study of VX-880 was announced in February 2021, and the treatment received fast-track status from the FDA in March of the same year.

typ-1-diabetes

What the study shows and what it does not

After the infusion, all 14 participants evaluated showed engraftment and islet cell function, as measured by the study. Among the 14 participants evaluated, neutropenia was the most common serious adverse event, with three cases; two participants died, one from cryptococcal meningitis and one from severe dementia resulting from the progression of a preexisting neurocognitive impairment. The study was funded by Vertex Pharmaceuticals, which is also the industry sponsor of the study recorded in the registry. In August 2026, the registered study was still ongoing, according to the registry, without randomization or blinding, with an estimated enrollment of 57.

The caveats behind the success

In an April 2025 statement, Breakthrough T1D praised the ongoing Zimislecel study as promising in all those treated, but also noted that there was then no approved manufactured cell therapy for type 1 diabetes. According to more recent information from February 2026, an FDA-approved islet cell therapy, Lantidra, already exists, diaTribe wrote. The diabetes portal diaTribe wrote in February 2026 that producing billions of high-quality islet cells derived from stem cells under strict regulatory standards remained complex and that companies were still refining their production methods. It also remains unclear what Vertex's announcement in early November 2026 that it would accelerate the development of VX-017 means for the Zimislecel approval application previously planned for 2026, which was contingent on continued evidence of safety and efficacy.

In comparison: two paths to the same goal

Vertex had pursued a second approach in parallel, in which islet cells derived from stem cells were implanted in a protective device without immunosuppression; the company discontinued this program, called VX-264, in 2025, according to Breakthrough T1D. The implanted cells had not produced enough insulin to justify further studies, the organization explained; the therapy had been generally safe and well tolerated in clinical trials but had missed its efficacy endpoint. The approach using immunosuppression had also shown as early as June 2023, in part B of the VX-880 study, that all six participants produced insulin on their own after treatment; two of them were insulin independent at least 12 months after treatment.

What could affect the timeline for approval

The therapy could probably become available no earlier than 2027 for people with type 1 diabetes and severe hypoglycemic episodes, diaTribe wrote in February 2026. It remains unclear whether the blood group restriction, the complex large-scale production of islet cells derived from stem cells and the new focus on VX-017 will change the timeline for Zimislecel.